Long non-coding RNAs (lncRNA) have been identified as key regulators of tumorigenesis and development. We aim to explore the biological functions and molecular mechanisms of lncRNA MIR200CHG in breast cancer. We found that MIR200CHG is highly expressed in breast cancer tissues and is related to the tumor size and histopathological grade. In vitro and in vivo experiments confirmed that MIR200CHG can promote breast cancer proliferation, invasion, and drug resistance. MIR200CHG directly binds to the transcription factor Y-box binding protein-1 (YB-1), and inhibits its ubiquitination and degradation. MIR200CHG regulates YB-1 phosphorylation at serine 102, thereby affecting the expression of genes related to tumor cell proliferation, apoptosis, invasion, and drug resistance. Additionally, MIR200CHG partially affects the expression of miR-200c/141-3p encoded by its intron region. Therefore, MIR200CHG can promote the proliferation, invasion, and drug resistance of breast cancer by interacting with and stabilizing YB-1, and has the potential to become a target for breast cancer treatment.

长链非编码 RNA (lncRNA) 已被确定为肿瘤发生和发展的关键调节因子。我们旨在探索lncRNA MIR200CHG在乳腺癌中的生物学功能和分子机制。我们发现MIR200CHG在乳腺癌组织中高表达，与肿瘤大小和组织病理分级有关。体内外实验证实MIR200CHG可促进乳腺癌增殖、侵袭和耐药。MIR200CHG 直接与转录因子 Y-box 结合蛋白-1 (YB-1) 结合，并抑制其泛素化和降解。MIR200CHG 在丝氨酸 102 处调节 YB-1 磷酸化，从而影响与肿瘤细胞增殖、凋亡、侵袭和耐药性相关的基因的表达。此外，MIR200CHG 部分影响由其内含子区域编码的 miR-200c/141-3p 的表达。因此，MIR200CHG可以通过与YB-1相互作用并稳定YB-1来促进乳腺癌的增殖、侵袭和耐药，有可能成为乳腺癌治疗的靶点。